AVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avalo Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-10.24.
During the past 3 years, the average EBITDA Per Share Growth Rate was 62.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avalo Therapeutics was 62.90% per year. The lowest was -37.40% per year. And the median was 22.15% per year.
For the Biotechnology subindustry, Avalo Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Avalo Therapeutics (NAS:AVTX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Avalo Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Armistice Capital Master Fund Ltd. | director, 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Caissa Capital Management Ltd. | 10 percent owner | PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110 |
Christopher Ryan Sullivan | officer: Interim CFO | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Garry Arthur Neil | officer: Chief Medical Officer | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Mitchell Chan | director | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
Stephen Smolinski | officer: Chief Commercial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Magnus Persson | director | 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Joseph M Miller | director | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Gilla Kaplan | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
June Sherie Almenoff | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Schond L. Greenway | officer: CFO & Treasurer | C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850 |
H Jeffrey Wilkins | officer: Chief Medical Officer | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Harrell James Archie Jr | officer: Chief Commercial Officer | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Illya Keith Maher | director | C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 06-06-2023
By sperokesalga sperokesalga • 05-22-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
By Stock market mentor Stock market mentor • 02-03-2023
By PurpleRose PurpleRose • 07-12-2022
By Stock market mentor Stock market mentor • 01-17-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By Marketwired • 09-26-2023
By sperokesalga sperokesalga • 05-10-2023
By Stock market mentor Stock market mentor • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.